Switch to subsequent line of treatment in children and adolescents with chronic myeloid leukemia (CML) treated with imatinib: Experience of the international registry for chronic myeloid leukemia in children and adolescents (I-CML-Ped Study)

Millot, FredericGuilhot, JoelleSuttorp, MeinolfMeunier, Anne SophieMeral, Güneş AdaletSedlacek, Petrde Bont, EvelineLi, Chi KongKalwak, KrzysztofLausen, BirgitteCulic, SrdjanaDe Moerloose, BarbaraBiondi, AndreaBaruchel, Andre2024-07-302024-07-302015-12-030006-4971https://hdl.handle.net/11452/43542Bu çalışma, 05-08, Aralık 2015 tarihlerinde Orlando[Amerika]’da düzenlenen 57th Annual Meeting of the American-Society-of-Hematology Kongresi‘nde bildiri olarak sunulmuştur.eninfo:eu-repo/semantics/closedAccessHematologySwitch to subsequent line of treatment in children and adolescents with chronic myeloid leukemia (CML) treated with imatinib: Experience of the international registry for chronic myeloid leukemia in children and adolescents (I-CML-Ped Study)Meeting Abstract00036801900505412623